Ro Offers Eli Lilly's Foundayo, the Newest GLP-1 Innovation Foundayo gives patients a new once daily pill option and expands Ros comprehensive weight loss formulary April 9, 2026 Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Companys newest oral GLP-1 innovation on the Ro platform, adding to Ros already comprehensive formulary of FDA-approved GLP-1s
Step 1: Initial Assessment You begin with a short online intake covering medical history, current medications, weight and health goals, and basic lifestyle factors
10.1016/S0149-7634(96)00005-X 211
Whether these are equivalent in biological effect is not proven through comparative human studies
I strongly caution patients against purchasing peptides from online retailers, social media advertisements, or sources that do not provide transparent documentation of their products composition and purity